To the Editor We read with interest the study by Simon and colleagues1 that analyzed data from the Nurses’ Health Study and the Health Professionals Follow-up Study and found that long-term aspirin use was associated with reduced risk for hepatocellular carcinoma (HCC). Because HCC carries a high mortality rate, prevention is key. We applaud the authors for investigating aspirin as a possible prevention method. However, we have several concerns.
Chien N, Yeo YH, Nguyen MH. Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin. JAMA Oncol. 2019;5(6):911. doi:10.1001/jamaoncol.2019.0614
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: